tbuckley/cabot-search huggingface dataset:
Soundings: Eternal youth
Authors: Imre Loefler
Journal: BMJ (2003)

Contemporary health care aims at conditions reported to have prevailed on Mount Olympus, where the assembled were immortal and retained youthfulness in looks, skills, and sexual powers.

The only member of the select group known to have had a disability was Hephaistos. No doubt nowadays his leg would be mended, probably with the help of metal implants, and thus, without a limp, he could pursue his wife, Aphrodite, more swiftly and prevent some of her escapades.

Short of the divine gifts of immortality and eternal youth, present day society, in its quest for Olympic conditions, has to rely on healthcare providers, who have learned to prolong life beyond supermaturity and who are able to restore youthful looks, skills and arrange for prodigious sexual performance at any age. The codex of human rights has been embellished with chapters devoted to new noses, hair transplants, the smoothing of wrinkles, tailor made breasts, lifted buttocks, liposuction, medically engineered looks, and enhanced energy and lust.

Ski slopes, golf courses, and tennis courts are populated by springy octogenarian replicas of Apollo, Hermes, and Pallas Athene, whose joints, hearts, vessels, and eyes have been made durable and elastic by means of metal and plastic implants and whose performance is enhanced by sophisticated gadgets. False teeth and an array of drugs help ageing alimentary canals to digest meals of richness unknown to the gods, and Ganymede, cupbearer to Zeus, would be exhausted if he were to replenish the drinks around the television sets, where mankind gathers to imbibe liquor and wisdom.

Penile implants, pumps, and drugs guarantee erectile performance and copulative endurance that would attract the wrathful envy of Zeus, while, thanks to hormones and group psychotherapy, old ladies break orgasmic records.

The immortality and the eternal youthfulness of the gods were divine attributes and did not have to be purchased. The pseudo youth of the inhabitants of the modern Mount Olympus comes dear. Because ageing has been declared a disease and health is considered to be a right, society has to pay for the youthful looks and the frolicking of the senescent. One wonders how much longer the young will be willing to foot the bill.
Relationship between thrombocytopenia and survival of patients with epithelial ovarian cancer (EOC) who received paclitaxel and carboplatin chemotherapy
Authors: S. Nagao, K. Fujiwara, N. Imafuku, Y. Kozuka, R. Kagawa, T. Oda, K. Maehata, H. Ishikawa, H. Koike, I. Kohno
Journal: Journal of Clinical Oncology (2005)

5049 Background: The purpose of this study was to evaluate the relationship between thrombocytopenia and survival of patients with EOC who received paclitaxel and carboplatin chemotherapy. Methods: Retrospective chart review was made for the patients with EOC diagnosed from 1997 to 2003 and treated by chemotherapy contains paclitaxel and carboplatin. Progression-free survival (PFS) and overall survival (OS) were compared between subgroups having various prognostic factors using Kaplan-Meier method and log rank test. A Cox proportional hazards model was applied to determine independent predictors for survival. Results: A total of 108 women were eligible for this study. The mean age at the time of diagnosis was 57 years (range, 26–77). There were 46 patients with stage I/II, 62 with stage III/IV. Median follow-up time was 23 months (range, 2 to 100 months). In the entire study population, there were 14 recurrence and 26 deaths, and the estimated 2-year PFS and OS were 62 and 80%, respectively. In univariate analysis, the decrease of platelet count > 90% at the first course of chemotherapy was a significant poor prognostic factor for PFS and OS (Hazard ratio [HR] = 0.32, 95% confidence interval [CI] = 0.04 to 0.57; p = 0.006, and HR = 0.39, 95% CI = 0.06 to 0.99; p = 0.048), although nadir grade of thrombocytopenia at the first course was not significant. The independent poor prognostic factors determined by Cox regression multivariate analysis were stage III/IV (p=0.002) and discontinuance of chemotherapy (p=0.012), decrease of platelet count >90% (p=0.008) for PFS, and stage III/IV (p=0.014), decrease of platelet count >90% (p=0.044) for OS. Conclusions: The percent decrease in platelet count at the first course of chemotherapy may be one of the important factors that predict a probability of recurrence and/or death in patients with EOC who received paclitaxel and carboplatin chemotherapy. No significant financial relationships to disclose.
Can intraperitoneal chemotherapy alter the natural course of ovarian cancer?
Authors: U Beller, E M Beckman, J L Speyer
Journal: Journal of Clinical Oncology (1986)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1986.4.6.1015 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3711955 Can intraperitoneal chemotherapy alter the natural course of ovarian cancer? U BellerxU BellerSearch for articles by this author , E M BeckmanxE M BeckmanSearch for articles by this author , J L SpeyerxJ L SpeyerSearch for articles by this author https://doi.org/10.1200/JCO.1986.4.6.1015 PDF "Can intraperitoneal chemotherapy alter the natural course of ovarian cancer?." Journal of Clinical Oncology, 4(6), p. 1015© 1986 by American Society of Clinical Oncology
A Naturally Occurring Antibody That Inhibits Fibrin Polymerization
Authors: W. Keith Hoots, Nadia A. Carrell, Robert H. Wagner, Herbert A. Cooper, Jan McDonagh
Journal: New England Journal of Medicine (1981)

A 13-year-old girl with chronic aggressive hepatitis, postnecrotic cirrhosis, ulcerative colitis, and a coagulation defect acquired an antibody that specifically interfered with fibrin formation. We sought to characterize the antibody and determine the mechanism of its inhibitory activity. The patient's purified fibrinogen was functionally normal; however, the antibody inhibited the self-assembly of fibrin and prolonged the clotting times of the patient's plasma. This antibody, which belonged to the IgG class of immunoglobulins, acted early in the polymerization process to inhibit the association of fibrin monomers, as indicated by a prolonged lag time and a decreased slope in the polymerization curves. It did not inhibit fibrinopeptide cleavage or fibrin cross-linking. Affinity chromatography indicated that the antibody bound strongly to both fibrinogen and fibrin monomer.
Alemtuzumab and Multiple Sclerosis
Authors: Reinhard Hohlfeld, Tania Kümpfel
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Case 4-2002
Authors: Hasan Bazari, Shamila Mauiyyedi
Journal: New England Journal of Medicine (2002)

Presentation of CaseA 75-year-old man was admitted to the hospital because of acute renal failure.He had undergone cystoprostatectomy and urethrectomy with construction of an ileal conduit five months earlier because of prostatic adenocarcinoma and urethral papillary transitional-cell carcinoma. The postoperative course was complicated by three weeks of paralytic ileus. Eighteen days before admission, laboratory tests were performed (Table 1). Two weeks before admission, malaise, low-grade fever, chills, and anorexia developed. Ofloxacin was prescribed, but the patient took it only sporadically. The symptoms did not improve. During an outpatient evaluation, a urographic examination (Figure 1) disclosed faint opacification of . . .
Case 47-1965
Authors: John D. Stoeckle, F. Daniel Foley
Journal: New England Journal of Medicine (1965)

Presentation of Case First admission. A sixty-six-year-old retired spray painter was admitted to the hospital because of spells of dizziness.Eleven days previously vertigo and diplopia developed suddenly, accompanied by numbness and motor weakness of the left arm and leg and slurring of speech. After a day of bed rest the symptoms and signs disappeared. Four days later he experienced another transient episode of dizziness with numbness in the left arm, and two days thereafter ataxia on walking was observed. There was no history of headache, nausea, vomiting, convulsions or hypertension.Nineteen years before admission lobar pneumonia and empyema developed . . .
Case 49-1977
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Donald C. Harrison, John T. Fallon
Journal: New England Journal of Medicine (1977)

Presentation of CaseA 69-year-old woman was admitted to the hospital because of melena.Twenty years earlier a diagnosis of hypothyroidism was made, and desiccated thyroid, 3 g daily, was prescribed. Eleven years before admission she first noted mild dyspnea. Four years before entry she was admitted to another hospital because of melena. Examination disclosed a murmur and signs of mild congestive heart failure. Extensive studies, including an exploratory laparotomy, failed to disclose a source of bleeding. Three years before admission bleeding recurred, and she came to this hospital, where she underwent a vagotomy, a partial gastrectomy with a Bilroth . . .
P7 Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON)
Authors: B Crestani, T Ogura, K Pelling, C Coeck, M Quaresma, M Kreuter, M Kaye
Journal: Thorax (2015)

<h3>Introduction</h3> The INPULSIS® trials assessed the efficacy and safety of nintedanib 150 mg twice daily in patients with idiopathic pulmonary fibrosis. Nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) compared with placebo in both trials. Patients who completed the 52-week treatment period and follow-up visit 4 weeks later (n = 807) could receive open-label nintedanib in an extension trial. <h3>Aim</h3> To assess the long-term efficacy and safety of nintedanib. <h3>Methods</h3> Patients treated with placebo in the INPULSIS® trials initiated treatment with nintedanib in the extension; patients treated with nintedanib continued to receive nintedanib. <h3>Results</h3> 734 patients were treated in the extension trial (430 continuing nintedanib; 304 initiating nintedanib). Baseline characteristics were similar between groups. For patients initiating nintedanib, mean (SD) duration of exposure was 16.0 (7.3) months; for patients continuing nintedanib, mean (SD) duration of exposure in the extension was 17.2 (6.6) months, resulting in a mean (SD) duration of exposure across the parent and extension trial of 29.2 (6.6) months. Among all patients treated in the extension, mean (SD) change in FVC from the start of the extension to week 48 was -87 (240) mL (-1.95 [7.09]% FVC predicted). In total, 92.8% of patients continuing nintedanib and 96.7% initiated on nintedanib had ≥1 adverse event during the extension. The most frequent adverse event was diarrhoea, reported in 63.3% of patients continuing nintedanib and 64.1% of patients initiated on nintedanib. <h3>Conclusion</h3> An interim analysis of data from the INPULSIS®-ON extension trial confirmed the efficacy and safety observed in the INPULSIS® trials.
Abstract 18861: Effects of Class III Antiarrhythmics on ICD Therapies and Clinical Outcomes: A Meta-analysis of Randomized Controlled Trials
Authors: Krishna Kancharla, Ahmet A Oktay, Shashi Kumar, Firas Kaddaha, Chaithanya Pamidimukala, Georges El Hayek, Cezar Benjo, Marcos Molina, Salim Kanaan, Eyal Herzog, Emad Aziz, Alexandre M Benjo
Journal: Circulation (2015)

Introduction: Implantable cardioverter defibrillators (ICD) prolong survival in patients with heart failure, reduced left ventricular ejection fraction (LVEF &lt;= 35%) and/or sustained ventricular arrhythmias (VA) by terminating VA with either anti-tachycardia pacing (ATP) or shock. However, ICD therapies are associated with significant pain, psychological distress, and increased risk for hospitalization and mortality. Antiarrhythmic drugs are commonly used to reduce frequency of VA in patients with ICD. We attempt to study the effects of class III antiarrhythmics on the frequency of ICD therapies, hospitalization and mortality. Methods: PubMed database was queried to identify prospective randomized controlled trials comparing class III antiarrhytmics to placebo on a standard background medical therapy in patients with an ICD and prior history of sustained VA (spontaneous/ treated/ induced) and/or sudden cardiac death. Information on appropriate ICD therapy, hospitalization and mortality was extracted. Fixed effect analysis was used when I2 ≤ 25% and p &gt;0.1, otherwise random effect analysis was performed. Results: After reviewing 2931 articles, seven trials that studied Amiodarone, Sotalol, Azimilide or Celivarone were included. A total of 2117 patients (87% males, mean age 63.8 years, mean LVEF 32.8%) were analyzed. 50.6% of the patients had at least one appropriate ICD therapy delivered and 4.5% died during the follow up. Antiarrhythmic drug usage significantly reduced the number of patients receiving ICD therapy by 55% (OR=0.45, 95% confidence interval [CI] 0.26-0.77, P=.004). There was no significant difference in mortality between treatment and placebo arms. Only 2 of the 7 trials reported number of hospitalizations and the sample size was insufficient for analysis. Conclusions: Class III antiarrhythmics significantly reduced ICD therapy for VA with no significant change in mortality.
Increased Insulin Receptors after Exercise in Patients with Insulin-Dependent Diabetes Mellitus
Authors: Oluf Pedersen, Henning Beck-Nielsen, Lise Heding
Journal: New England Journal of Medicine (1980)

Physical exercise is known to improve glucose tolerance and diminish insulin requirements in patients with well-controlled diabetes mellitus. To ascertain whether these effects of exercise are associated with alterations in insulin receptors, we studied [125I]insulin binding to erythrocytes and monocytes in athletically untrained young men with insulin-treated diabetes during three hours of postprandial bicycle exercise (nine patients) and two hours of exercise during fasting (eight patients). Compared with control periods, postprandial exercise, as well as exercise during fasting, significantly increased insulin binding to erythrocytes and monocytes at an insulin-tracer concentration of 34 pmol per liter. We suggest that similar changes occur in working muscle cells and contribute to the improved glucose tolerance induced by exercise.
The Prognostic Value of Residual Coronary Stenoses After Functionally Complete Revascularization
Authors: Yuhei Kobayashi, Chang-Wook Nam, Pim A.L. Tonino, Takumi Kimura, Bernard De Bruyne, Nico H.J. Pijls, William F. Fearon
Journal: Journal of the American College of Cardiology (2016)
The Incidence of Swollen Arms after Radical Mastectomy and Suggestions for Prevention
Authors: Ernest M. Daland
Journal: New England Journal of Medicine (1950)

ON a number of occasions when a patient has been told that she would have to have her breast removed she has asked if that meant loss of use of her arm. There have been enough cases in the community in which postoperative swelling of the arm has interfered with or destroyed the function of the arm for this fear to be constantly found among women. Stewart and Treves1 state "conservatively speaking, some degree of swollen arm supervenes after radical mastectomy in about 70 per cent of women." Macdonald2 says "after radical mastectomy, 40 to 50 per cent of women . . .
Neuroblastoma: A spectrum of cells isolated from bone marrow of patients
Authors: G. Saulnier Sholler, S. Illenye, M. Warzynski, R. E. Brown, P. J. Lescault, K. Koto, L. Dorf, J. Bond
Journal: Journal of Clinical Oncology (2009)

10055 Background: Neuroblastoma is the most common extracranial solid tumor in children and, when disseminated, portends a poor prognosis. Even with aggressive combinations of chemotherapy, surgery, autologous bone marrow transplant and radiation, long-term survival remains at 30%. Better detection of the 70% of patients who will relapse is essential. One possibility may be in the better detection of minimal residual disease and improved classification of the heterogeneous populations of cells present in the bone marrow with respect to risk. Methods: Bone marrow aspirates of patients with neuroblastoma were harvested and placed in neurobasal culture media and heparinized vacutainer tubes. They were analyzed by 6-color flow cytometry (CD56+, GD2+, CD81+, CD45−, CD9+, CD34+or−). Neuroblastoma cells and neurospheres were grown. mRNA expression analysis using U133 chips, immunofluorescence, and immunohistochemistry were performed. Mouse xenograft models were used to evaluate tumorigenicity of patient cells injected subcutaneously. Results: Flow cytometry can detect neuroblastoma cells as low as 0.001% within the heparinized samples and used to characterize the cultured cells. Cell culture showed a spectrum of neuronal morphology. Neurospheres express lower levels of GD2, TrkB, and CD56 compared to adherent neuroblastoma (consistent results were obtained using flow cytometry, immunofluoresence, immunohistochemistry, and mRNA expression analysis). Tumorigenicity was confirmed using mice injected subcutaneously with patient neurospheres tumors were present at the injection site and metastasized. Conclusions: Bone marrow aspirates of patients with neuroblastoma can be analyzed for the presence of neuroblastoma initiating cells which can be further characterized. This may play an important role in clinical decision making for therapeutic end points in a cancer that is likely to relapse. No significant financial relationships to disclose.
Abstract LB-247: Mutation and functional analysis of <i>PIK3CA</i> and <i>PIK3R1</i> in endometrial cancer
Authors: Lydia Wai Ting Cheung, Bryan T. Hennessy, Jie Li, Shuangxing Yu, Andrea P. Myers, Bojana Djordjevic, Yiling Lu, Katherine Stemke-Hale, Fan Zhang, Zhenlin Ju, Lewis C. Cantley, Steve E. Scherer, Han Liang, Karen H. Lu, Broaddus R. Russell, Gordon B. Mills
Journal: Cancer Research (2011)

Abstract The phosphatidylinositol 3 kinase (PI3K) pathway is the most frequently activated pathway across multiple tumor lineages and this is a potential therapeutic target. As a critical step to accelerate therapeutic development in endometrial cancer, we performed a comprehensive analysis of mutation and function of PI3K pathway members in a set of 243 highly characterized endometrial tumors. Whole gene resequencing revealed the highest frequencies of mutation in the PI3K pathway of any tumor lineage including PTEN (44%), PIK3CA (40%; encoding the p110α catalytic subunit of PI3K) and PIK3R1 (20%; encoding the p85a regulatory subunit). Indeed, when complete protein loss is considered, almost 80% of endometrioid endometrial cancers demonstrate an aberration in the PI3K pathway. Remarkably, mutations in the PI3K pathway were not mutually exclusive and indeed co-existence of PIK3CA or PIK3R1 mutation with heterozygous PTEN mutation occurred at frequencies higher than predicted by the frequency of each lesion alone. High-throughput reverse-phase protein array suggested that the dominant signaling effects occurred with PTEN protein loss and that PIK3CA or PIK3R1 mutation functionally mimic PTEN protein loss as indicated by protein markers including phosphorylated Akt and stathmin. Thus it appears likely that co-mutations in the PI3K pathway are selected to compensate haploinsufficiency of PTEN due to PTEN heterozygous mutation. To determine the functional consequences of mutations in PIK3R1, we demonstrated that several somatic PIK3R1 mutations tested conferred cytokine-independent growth on interleukin-3-dependent Ba/F3 cells and induced Akt phosphorylation in endometrial cancer cell lines indicating that they were gain of function mutations likely acting as oncogenes. Strikingly two of the gain of function mutations (E160* and R348*) lacked the ability to bind to the p110 catalytic subunit and E160* failed to bind to both p110 and PTEN. We demonstrate that E160* disrupts a novel mechanism of pathway regulation wherein p85 binds and stabilizes PTEN. Together, the data indicate that the PI3K pathway is targeted in the vast majority of endometrioid endometrial cancers representing a novel opportunity for implementation of targeted therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-247. doi:10.1158/1538-7445.AM2011-LB-247
Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission
Authors: Anne Aupérin, Rodrigo Arriagada, Jean-Pierre Pignon, Cécile Le Péchoux, Anna Gregor, Richard J. Stephens, Paul E.G. Kristjansen, Bruce E. Johnson, Hiroshi Ueoka, Henry Wagner, Joseph Aisner
Journal: New England Journal of Medicine (1999)

Prophylactic cranial irradiation reduces the incidence of brain metastasis in patients with small-cell lung cancer. Whether this treatment, when given to patients in complete remission, improves survival is not known. We performed a meta-analysis to determine whether prophylactic cranial irradiation prolongs survival.
Evaluation of Myocardial State by Synchronized Radiography and Exercise
Authors: William J. Phillips, Hugh B. Higginbotham, Herbert Frerking, Robert Paine
Journal: New England Journal of Medicine (1966)

ALTHOUGH cardiac response to exercise has been studied in many ways, the immediate changes in heart size have received little attention, and almost no clinical application. Normal laboratory animals have consistentlv responded to exercise with an immediate reduction in cardiac diameter.1 Except for early, inconsistent radiographic studies2 observations of the immediate effects of exertion upon the heart size of man have been limited to a few measurements employing operative or technical procedures so complex as to limit their application sharply. The results, however, have proved consistent. Radiographs of 4 hearts marked with metal clips at thoracotomy exhibited a reduction in . . .